Novo Nordisk has twin successes with once-weekly insulin

With another two phase III trials of once-weekly icodec successfully behind the Danish pharmaceutical firm, there is only one last remaining in the six-study long Onwards program.

Photo: Tidsvilde Stine/Ritzau Scanpix

Novo Nordisk has met its primary endpoint in two phase III studies of once-weekly insulin icodec, the Danish pharmaceutical company has announced in a press release.

The two studies, Onwards 3 and Onwards 4, are a part of the Onwards program, which is comprised of 6 studies. With three sub-programs having already reported promising results, there is now only one left, expected to conclude during the second half of 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs